CDMOs offering Process Development with Oligonucleotide
Process Development combined with Oligonucleotide is a common shortlist filter for sponsors evaluating CDMO partners. This explore page lists organizations that publicly map to both dimensions, so you can move from taxonomy browsing to a tighter candidate set without rebuilding filters from scratch.
Profiles here are fit-first: open each listing for scope, geography, regulatory posture, and provenance-backed facts. The directory does not rank these rows as a single "best" answer — use them to assemble a right-sized outreach list for your program stage and quality bar.
When you need adjacent criteria (indications, claim status, or cross-category search), continue to the main search experience and layer filters on top of this service × modality starting point.
Auto-generated by BioBM Editorial AI.
Matching companies
- Ajinomoto Bio-Pharma Services
Ajinomoto Bio-Pharma Services is a global contract development and manufacturing organization (CDMO) dedicated to improving the health of humankind through adaptive solutions and responsive service. The company offers a comprehensive portfolio of manufacturing and development…
- Almac Group
Global CDMO with 7,900+ employees across 18 facilities, offering integrated drug development and manufacturing services including analytical development, formulation, process development, fill-finish, and specialized chemistry capabilities.
- BSP Pharmaceuticals
BSP Pharmaceuticals is a CDMO specializing in development and manufacturing of cytotoxic oncology drugs, ADCs, peptides, proteins, and lipid-based formulations from preclinical GLP through commercial supply.
- Bachem
Global leader in peptide and oligonucleotide development and manufacturing, offering GMP-compliant clinical and commercial supply from early research through commercial scale.
- BioVectra
North American CDMO specializing in clinical-to-commercial biologics, small molecules, HPAPIs, and bioreagents with 50+ years of microbial fermentation and complex chemistry expertise across cGMP facilities in Canada.
- CordenPharma
Full-service CDMO offering cGMP development and manufacturing of APIs, lipid excipients, drug products, injectables, peptides, LNPs, oligonucleotides, and oral solid dose across 10 facilities in 6 countries with 3000+ employees.
- Maravai LifeSciences
Leading provider of nucleic acid products, custom enzymes, and bioprocess analytics supporting vaccine, therapeutic, and diagnostic development from discovery through commercialization, with mRNA CDMO services including proprietary CleanCap® capping technology.
- PharmaBlock
Leading provider of innovative chemistry products and services for pharmaceutical R&D and commercial manufacturing, with expertise in process development, GMP manufacturing, and low-carbon chemistry solutions.
- Pharmaron
Premier life science CRO and CDMO offering integrated R&D and manufacturing across drug discovery, preclinical, clinical development, and commercialization for small molecules, biologics, and cell & gene therapies. 25,000+ employees across China, US, and UK.
- Syngene International
Innovation-led CRDMO offering integrated scientific services from early discovery through commercial manufacturing, with cGMP-compliant facilities, 5,200+ scientists, and a new 50,000-liter single-use bioreactor capacity in the U.S.
- TriLink BioTechnologies
TriLink manufactures mRNA, oligonucleotides, and modified nucleotides with proprietary CleanCap® capping technology achieving >95% Cap1 efficiency, supported by in-house analytical method development and a 118,000 sq ft GMP-capable facility.
Related: Process Development service page · Oligonucleotide modality page
Markdown mirror: /explore/svc_process_development/mod_oligo.md